Renaissance Technologies LLC Invests $1.52 Million in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Renaissance Technologies LLC bought a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 878,448 shares of the company's stock, valued at approximately $1,520,000. Renaissance Technologies LLC owned 0.43% of Taysha Gene Therapies as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN grew its holdings in Taysha Gene Therapies by 43.7% during the fourth quarter. Wells Fargo & Company MN now owns 103,384 shares of the company's stock worth $179,000 after acquiring an additional 31,457 shares during the period. Geode Capital Management LLC grew its holdings in Taysha Gene Therapies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company's stock worth $6,182,000 after acquiring an additional 9,591 shares during the period. Wellington Management Group LLP grew its holdings in Taysha Gene Therapies by 26.4% during the fourth quarter. Wellington Management Group LLP now owns 585,594 shares of the company's stock worth $1,013,000 after acquiring an additional 122,402 shares during the period. Norges Bank acquired a new stake in Taysha Gene Therapies during the fourth quarter worth about $2,528,000. Finally, EntryPoint Capital LLC grew its holdings in Taysha Gene Therapies by 127.5% during the fourth quarter. EntryPoint Capital LLC now owns 61,495 shares of the company's stock worth $106,000 after acquiring an additional 34,468 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Trading Up 1.1 %

Taysha Gene Therapies stock traded up $0.02 during trading on Tuesday, reaching $1.82. 1,264,665 shares of the company were exchanged, compared to its average volume of 2,704,866. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The company has a market capitalization of $373.20 million, a P/E ratio of 2.89 and a beta of 0.96. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock's 50 day simple moving average is $1.55 and its two-hundred day simple moving average is $1.80.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have commented on TSHA. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Monday. Finally, JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Monday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $6.63.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.